Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07233447

Prevalence of H. Pylori in Stomach Cancers in the West Indies

The incidence and mortality of stomach cancer are higher in the French West Indies than in mainland France. The prevalence of H. pylori infection associated with this cancer remains unknown in these populations. The main objective of the study is to estimate the prevalence of H. Pylori detected by immunohistochemistry in patients newly diagnosed with cancer.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Cabinet Galeries de Houelbourg, Baie-Mahault, Guadeloupe

Loading trial locations.

About this study

Stomach cancer is the 4th most common cancer site in the world and the 3rd cause of mortality. It is associated with infection by the Helicobacter Pylori bacterium, which colonizes the gastric mucosa in 80% of cases. The decrease of the prevalence of H. pylori infection in developed countries with the advent of antibiotic treatments is responsible for the decrease in the incidence of stomach cancer. But in the French West Indies, stomach cancer remains in excess incidence and mortality compared to France. The prevalence of H. pylori infection remains unknown, both in general population and in patients with stomach cancer. Eating habits combining high consumption of salt, meat and smoked fish could partly explain these high incidences. Furthermore, recent observations suggest that environmental risk factors (pesticides pollution) could also be involved in the occurrence of this cancer. Estimating the prevalence of H. pylori in stomach cancers will improve the epidemiological knowledge of this cancer with high incidence rates and prevention measures.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient over 18 years of age residing in Guadeloupe for more than 6 months and with a primary diagnosis of gastric cancer
  • Patient having read the information note and having signed the consent to participate in the study
  • Patient with social security coverage.

Exclusion criteria

  • Refusal to participate.
  • Patient who could not answer the questionnaires
  • Patient not affiliated to a social security scheme
  • Patient under legal protection (judicial safeguard, guardianship, curatorship, etc.)
  • Pregnant or breastfeeding woman
  • Subject participating in another research study that includes an exclusion period still ongoing at the time of pre-inclusion

Treatment and study plan

Primary outcomes

  1. detection of H. Pylori in immunohistochemistry

    Time frame: Baseline

    Detection of Helicobacter pylori will be performed by immunohistochemistry (IHC) on gastric biopsy samples collected at inclusion. The procedure aims to identify the presence of H. pylori antigens within the gastric mucosa using specific antibodies. The test will be conducted in a certified pathology laboratory according to standard diagnostic protocols. Results will be reported as positive or negative for H. pylori infection.

Secondary outcomes

  1. positivity of anti H. Hylori serology by Elisa test

    Time frame: Baseline

    Positivity of anti-Helicobacter pylori serology determined by ELISA test performed on serum samples collected at inclusion. Results will be reported as positive or negative for H. pylori antibodies.

Study contacts

Contact information is provided by the study sponsor or research team.

Mélanie petapermal, Master degree

CONTACT

[email protected]

+590590934667

Valérie Hamony Soter

CONTACT

[email protected]

+590590934677

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de la Guadeloupe

Other

Registry information

Acronym: PyloCaGe

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Nov 18, 2025
Registry last updated
Nov 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.